Regulatory News:
Genomic Vision(Paris:GV) (the "Company" FR0011799907 GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced that it has expanded its EasyComb services in the field of drug discovery driven by the healthcare market need to develop novel and specific drugs to stop cancer growth.
During the past ten years, the proprietary replication combing assay (RCA) has become a standard tool for understanding the function and mechanism of drugs used in cancer treatment. Genomic Vision has partnered and contributed to this field with key academic institutions worldwide to ensure successful adoption of its technology resulting in many high impact scientific publications.
One recent example is the study published in the journal Molecular Cell (Cong et al., 2021by the University of Massachusetts Medical School which used RCA to analyze the replication gaps in BRCA1 to determine the sensitivity of poly (ADP-ribose) polymerase inhibition (PARPi), a new class of potential drug targets.
"Our findings establish a model to help further develop targeted treatment with PARPi, such that combined therapies maximize exposed lagging strand gaps," said Sharon Candor, PhD, University of Massachusetts Medical School.
Genomic Vision has experienced significant increase in demand for replication analysis in the past few months from globally recognized leaders in the pharma and biotech segments. These companies are investigating novel drugs for inhibition of the growth of cancer cells by surveying recombination and replication fork kinetics. This has enabled the expansion of Genomic Vision's services and will allow the company to take a leadership position in providing tools and services in the specific analysis of DNA replication in drug discovery.
"Based on the significant amount of replication analysis data accumulated over the past years, we are now expanding our services to include an end-to-end approach, including enhancement of our analysis pipeline that includes artificial intelligence-based detection. This will allow the pharmaceutical and biotechnology industries to use RCA data as a unique tool in finding new classes of drugs for cancer treatment," said Dominique Remy-Renou, CEO of Genomic Vision.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC Mid Small and CAC All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the universal registration document filed with the AMF on February 9, 2021 under reference number R.21-002, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005468/en/
Contacts:
Genomic Vision
Dominique Remy-Renou
CEO
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com
Ulysse Communication
Press Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com
NewCap
Investor Relations
& Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu
